Antithymocyte Globulin and Cyclosporine in Treating Patients With Myelodysplastic Syndrome
Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
The main objective of this trial is to evaluate the efficacy and toxicity of intensive
immuno-suppression with ATG + CSA versus best supportive care in patients with transfusion
dependent low and intermediate risk myelodysplastic syndrome (MDS).